Chronic kidney disease (CKD) affects nearly 36 million people. “CKD is a real public health crisis, and one that’s steadily rising,” said Merlin Thomas, M.B.Ch.B., Ph.D., FRACP, a professor of ...

SAN DIEGO, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (Nasdaq: TVTX) and CSL Vifor today announced that Swissmedic has granted temporary marketing authorization for FILSPARI for the ...

Medically reviewed by David Ozeri, MD IgA nephropathy is the most common primary cause of kidney inflammation worldwide. Primary means the inflammation starts in your kidneys, not as a result of ...

If approved, FILSPARI would be the first and only FDA-approved treatment for FSGS, a rare kidney condition and a leading cause of kidney failure SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. ...

In the UK, more than 10 per cent of the population is estimated to have some stage of chronic kidney disease and more than 600,000 people develop some form of acute kidney injury – when the kidneys ...

Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that the U.S. Food and Drug Administration (FDA) has informed the Company that following further review of the supplemental New Drug ...

Kidney disease is a growing health concern worldwide, affecting millions of people. It is often referred to as a silent killer because symptoms may not appear until significant damage has been done.

We often associate the word "attack" with the heart, sudden, severe, and often life-threatening. But what many don’t realise is that kidneys, too, can suffer a similar crisis. It’s called a kidney ...

Creatinine has been, is now, and will be for the foreseeable future our easiest way to monitor kidney function. However, the inadequacies and limitations of creatinine as such a marker are well ...

A kidney transplant can be an important and sometimes necessary option for someone with severe lupus kidney disease. If you are thinking about seeking a kidney transplant (or if you are considering ...

SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that the U.S. Food and Drug Administration (FDA) has informed the Company that following further review of the ...